Home/Filings/4/0001181431-08-053261
4//SEC Filing

Maroun Richard E 4

Accession 0001181431-08-053261

CIK 0001141399other

Filed

Sep 14, 8:00 PM ET

Accepted

Sep 15, 7:28 PM ET

Size

13.5 KB

Accession

0001181431-08-053261

Insider Transaction Report

Form 4
Period: 2008-09-10
Maroun Richard E
Chief Administrative Officer
Transactions
  • Disposition to Issuer

    Incentive Stock Option

    2008-09-10$15.34/sh26,064$399,8220 total
    Exercise: $7.66Exp: 2016-05-19Common Stock (26,064 underlying)
  • Disposition to Issuer

    Common Stock

    2008-09-10410 total(indirect: Stock owned by Son)
  • Disposition to Issuer

    Common Stock

    2008-09-10730 total(indirect: Stock owned by Daughter)
  • Disposition to Issuer

    Common Stock

    2008-09-101000 total
  • Disposition to Issuer

    Nonqualified Stock Option (Right to Purchase)

    2008-09-10$15.34/sh42,300$648,8820 total
    Exercise: $7.66Exp: 2016-05-19Common Stock (42,300 underlying)
Footnotes (3)
  • [F1]Disposed of pursuant to the Agreement and Plan of Merger, dated as of July 6, 2008, among Fresenius SE, Fresenenius Kabi Pharmaceuticals Holding, Inc. (formerly Frensenius Kabi Pharmaceuticals Holding LLC), Fresenius Kabi Pharmaceuticals, LLC (?Merger Sub?) and APP Pharmaceuticals, Inc. (?APP?), whereby Merger Sub merged into APP with APP continuing as the surviving company and an indirect wholly owned subsidiary of Fresenius SE (the ?Merger?), in exchange for (x) an amount in cash equal to $23.00 plus (y) a contingent value right issued by Holdco.
  • [F2]Pursuant to the Merger, this option, which was granted on May 19, 2006 and 25% of which vests per year for four years from the anniversary of the grant date, was cancelled in exchange for a cash payment of $199,650, which represents the excess of $23.00 per share over the exercise price per share of this option.
  • [F3]Pursuant to the Merger, this option, which was granted on May 19, 2006 and 25% of which vests per year for four years from the anniversary of the grant date, was cancelled in exchange for a cash payment of $324,018, which represents the excess of $23.00 per share over the exercise price per share of this option.

Issuer

APP Pharmaceuticals, Inc.

CIK 0001141399

Entity typeother

Related Parties

1
  • filerCIK 0001364590

Filing Metadata

Form type
4
Filed
Sep 14, 8:00 PM ET
Accepted
Sep 15, 7:28 PM ET
Size
13.5 KB